1–10 of 69 results for Wet AMD
Treatment Burden and Vision Analysis of Anti-VEGF Therapies for the Treatment of Neovascular AMD
Rahul Komati, MD
Annual Meeting Talks
2020
Predicting Long-term Response to Ranibizumab After Three Injections in Patients With Age-Related Macular Degeneration
Paul Hahn, MD, PhD, FASRS
Two-Year Results From the Subretinal RGX-314 Gene Therapy Phase 1/2a Study for the Treatment of Neovascular AMD
Robert L. Avery, MD
Updates from the Field
2021
Ziv-aflibercept Efficacy in Better Regulating Neovascular AMD (ZEBRA) Trial
Kapil G. Kapoor, MD
On Demand Cases, Courses, and Papers
2019
Treatment course and outcomes of neovascular age-related macular degeneration in patients receiving intraocular pressure-lowering drops
Bobeck S Modjtahedi, MD
Real World Patient and Clinical Characteristics in Treatment Naive Neovascular Age-Related Macular Degeneration
Matthew P. Ohr, MD
PRN cycles of three monthly anti-VEGF injections in neovascular AMD: 12 and 24 months results.
Touka Banaee, MD
It’s the Patient, Not the Agent: An Assessment of Anti-VEGF Extended Dosing Intervals in Patients With nAMD
David A. Eichenbaum, MD, FASRS
Intravitreal Bevacizumab vs. Bevacizumab with Dexamethasone for the Treatment of Exudative Age-Related Macular Degeneration
Reda Issa, MD
Does Anti-VEGF Therapy Affect the Rate of Expansion of Geographic Atrophy in Patients with Neovascular AMD Managed by a Treat-Extend-Stop Protocol?
Sean David Adrean, MD, FAAO, FASRS